{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:51:21Z","timestamp":1790830281513,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.rceng.2019.10.012","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T10:25:50Z","timestamp":1603448750000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Diabetic cardiomyopathy"],"prefix":"10.1016","volume":"222","author":[{"given":"A.","family":"Lorenzo-Almor\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cepeda-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3.","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2019.10.012_bib0005","first-page":"358","article-title":"Asthma and diabetes mellitus","volume":"3","author":"Leyden","year":"1881","journal-title":"Zeitschr Klin Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(54)90924-1","article-title":"Diabetic angiopathy: a specific vascular disease","volume":"266","author":"Lundbaek","year":"1954","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2019.10.012_bib0015","first-page":"63","article-title":"Is there a diabetic cardiopathy?","author":"Lundbaek","year":"1969","journal-title":"Pathogenetische Fakt des Myokardinfarkts"},{"key":"10.1016\/j.rceng.2019.10.012_bib0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12933-017-0506-x","article-title":"Diagnostic approaches for diabetic cardiomyopathy","volume":"16","author":"Lorenzo-Almor\u00f3s","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jdi.12250","article-title":"Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage","volume":"5","author":"Liu","year":"2014","journal-title":"J Diabetes Investig"},{"issue":"25","key":"10.1016\/j.rceng.2019.10.012_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCULATIONAHA.106.679597","article-title":"Diabetic cardiomyopathy revisited","volume":"115","author":"Boudina","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0040","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2019.10.012_bib0045","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.amjmed.2008.03.046","article-title":"Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options","volume":"121","author":"Aneja","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00592-010-0180-x","article-title":"The diabetic cardiomyopathy","volume":"48","author":"Tarquini","year":"2011","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0055","article-title":"Second in a series on diabetes and the heart: diabetic cardiomyopathy \u2014 mechanisms and mode of diagnosis. E-Journal-of-Cardiology-Practice\/Volume-14\/Second-in-a-series-on-diabetes-and-the-heart-diabetic-cardiomyopathy-mechanisms-and-mode-of-diagnosis","volume":"14","author":"Matshela","year":"2016","journal-title":"E J Clin Pract ESC"},{"key":"10.1016\/j.rceng.2019.10.012_bib0060","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/VHRM.S11681","article-title":"Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies","volume":"21","author":"Voulgari","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.rceng.2019.10.012_bib0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2019.10.012_bib0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/00365513.2016.1155230","article-title":"Myocardial dysfunction and cardiovascular disease in type 2 diabetes","volume":"76","author":"Ofstad","year":"2016","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.rceng.2019.10.012_bib0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/heartjnl-2016-310342","article-title":"Diabetic cardiomyopathy","volume":"105","author":"Lee","year":"2018","journal-title":"Heart heartjnl-2"},{"key":"10.1016\/j.rceng.2019.10.012_bib0080","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2337\/diacare.28.3.612","article-title":"The association between glucose abnormalities and heart failure in the population-based Reykjavik study","volume":"28","author":"Thrainsdottir","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2019.10.012_bib0085","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2019.10.012_bib0090","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patientswith chronic heart failure and reduced left-ventricular systolicfunction taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"Mcmurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2019.10.012_bib0095","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2337\/diacare.26.10.2791","article-title":"Diabetes and idiopathic cardiomyopathy: a nationwide case-control study","volume":"26","author":"Bertoni","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2019.10.012_bib0100","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2019.10.012_bib0105","first-page":"194","article-title":"Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial","volume":"15","author":"Sarma","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2019.10.012_bib0110","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","article-title":"Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (Irbesartan in Heart Failure with preserved ejection","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2019.10.012_bib0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.rceng.2019.10.012_bib0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cpcardiol.2014.09.002","article-title":"Concomitant diabetes mellitus and heart failure","volume":"40","author":"Dei Cas","year":"2015","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2019.10.012_bib0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2019.10.012_bib0140","doi-asserted-by":"crossref","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u2018Thrifty Substrate\u2019 hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2019.10.012_bib0145","first-page":"78","article-title":"The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2019.10.012_bib0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","article-title":"Metabolic remodelling in heart failure","volume":"15","author":"Bertero","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart \u2014 an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0160","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.rceng.2019.10.012_bib0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbabio.2018.05.019","article-title":"Mitochondrial uncoupling, ROS generation and cardioprotection","volume":"1859","author":"Cadenas","year":"2018","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"10.1016\/j.rceng.2019.10.012_bib0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1016\/j.rceng.2019.10.012_bib0175","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1096\/fj.00-0351com","article-title":"Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart","volume":"15","author":"Young","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.rceng.2019.10.012_bib0180","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cmet.2016.07.010","article-title":"Nutritional ketosis alters fuel preference and thereby endurance performance in athletes","volume":"24","author":"Cox","year":"2016","journal-title":"Cell metab"},{"key":"10.1016\/j.rceng.2019.10.012_bib0185","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/bmb.2005.49403304246","article-title":"Ketone bodies as a fuel for the brain during starvation","volume":"33","author":"Owen Oliver","year":"2005","journal-title":"Biochem Mol Biol Educ"},{"key":"10.1016\/j.rceng.2019.10.012_bib0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.116.022141","article-title":"Failing heart and starving brain: ketone bodies to the rescue","volume":"134","author":"Taegtmeyer","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0195","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.rceng.2019.10.012_bib0200","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ceca.2014.08.004","article-title":"Calcium signaling in diabetic cardiomyocytes","volume":"56","author":"Pereira","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.rceng.2019.10.012_bib0205","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","article-title":"Activation of Na+\/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure","volume":"103","author":"Nakamura","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002183","article-title":"Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport","volume":"4","author":"Lambert","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rceng.2019.10.012_bib0215","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/BJ20100717","article-title":"Translocation of the Na+\/H+ exchanger 1 (NHE1) in cardiomyocyte responses to insulin and energy-status signalling","volume":"432","author":"Lawrence","year":"2010","journal-title":"Biochem J"},{"issue":"1\u20132","key":"10.1016\/j.rceng.2019.10.012_bib0220","first-page":"1","article-title":"The effect of leptin on Na(+)-H(+) antiport (NHE 1) activity of obese and normal subjects erythrocytes","volume":"183","author":"Konstantinou-Tegou","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0225","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1161\/01.HYP.0000102863.23854.0B","article-title":"Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes","volume":"42","author":"Karmazyn","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.rceng.2019.10.012_bib0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCRESAHA.118.310082","article-title":"Calcium signaling and reactive oxygen species in mitochondria","volume":"122","author":"Bertero","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0235","first-page":"112","article-title":"Myocardial cell death in human diabetes","volume":"87","author":"Frustaci","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jacc.2014.04.083","article-title":"Metabolic impairment in heart failure: the myocardial and systemic perspective","volume":"64","author":"Doehner","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0245","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/01.CIR.0000012466.50373.E8","article-title":"Adaptation and maladaptation of the heart in diabetes: part I","volume":"105","author":"Taegtmeyer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0250","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"Pt 16","key":"10.1016\/j.rceng.2019.10.012_bib0255","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1242\/jcs.114.16.2903","article-title":"PKB\/Akt: a key mediator of cell prolife-ration, survival and insulin responses?","volume":"114","author":"Lawlor","year":"2001","journal-title":"J Cell Sci"},{"key":"10.1016\/j.rceng.2019.10.012_bib0260","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.yjmcc.2010.02.012","article-title":"Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy","volume":"48","author":"Kr\u00fcger","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0265","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2005.02.093","article-title":"Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure","volume":"46","author":"Doehner","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0270","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence Supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0285","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2016.05.019","article-title":"The HFpEF obesity phenotype: the elephant in the Room.","volume":"68","author":"Kitzman","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0290","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/01.RES.0000163635.62927.34","article-title":"Adipose tissue, inflammation, and cardiovascular disease","volume":"96","author":"Berg","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0295","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cardiores.2007.03.008","article-title":"Local adipose tissue depots as cardiovascular risk factors","volume":"75","author":"Thalmann","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0300","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-2008-1062724","article-title":"The double role of epicardial adipose tissue as pro- and anti-inflammatory organ","volume":"40","author":"Iacobellis","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0305","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nrendo.2015.58","article-title":"Local and systemic effects of the multifaceted epicardial adipose tissue depot","volume":"11","author":"Iacobellis","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0310","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s10517-017-3860-5","article-title":"Adipokine and cytokine profiles of epicardial and subcutaneous adipose tissue in patients with coronary heart disease","volume":"163","author":"Gruzdeva","year":"2017","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00380-012-0315-9","article-title":"Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes","volume":"29","author":"Bambace","year":"2014","journal-title":"Heart Vessels"},{"key":"10.1016\/j.rceng.2019.10.012_bib0320","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijcard.2012.05.009","article-title":"Heart failure epicardial fat increases atrial arrhythmogenesis","volume":"167","author":"Lin","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0325","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10554-014-0579-5","article-title":"Association of epicardial and peri-atrial adiposity with the presence and severity of non-valvular atrial fibrillation","volume":"31","author":"Yorgun","year":"2017","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.rceng.2019.10.012_bib0330","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijcard.2006.04.016","article-title":"A relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects","volume":"115","author":"Iacobellis","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0335","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.amjcard.2015.07.067","article-title":"Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation","volume":"116","author":"Soucek","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0340","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5551\/jat.3632","article-title":"Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels","volume":"17","author":"Horiuchi","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.rceng.2019.10.012_bib0345","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"3","author":"Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0350","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/13813455.2013.796996","article-title":"Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis","volume":"119","author":"Cignarelli","year":"2013","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.rceng.2019.10.012_bib0355","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0360","article-title":"Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models","volume":"7","author":"Suzuki","year":"2014","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.rceng.2019.10.012_bib0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bcpt.12402","article-title":"Antidiabetic agents and endothelial dysfunction \u2014 beyond glucose control","volume":"117","author":"Eriksson","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0370","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00059-011-3429-4","article-title":"Diabetic cardiomyopathy \u2014 fact or fiction?","volume":"36","author":"Maisch","year":"2011","journal-title":"Herz"},{"key":"10.1016\/j.rceng.2019.10.012_bib0375","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","article-title":"Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction","volume":"5","author":"Dunlay","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.rceng.2019.10.012_bib0380","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCULATIONAHA.105.587519","article-title":"Myocardial structure and function differ in systolic and diastolic heart failure","volume":"113","author":"Van Heerebeek","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0390","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCULATIONAHA.110.981431","article-title":"Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum","volume":"123","author":"De Keulenaer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0395","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10554-014-0536-3","article-title":"Left and right atrial phasic function and deformation in untreated patients with prediabetes and type 2 diabetes mellitus","volume":"31","author":"Tadic","year":"2015","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.rceng.2019.10.012_bib0400","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.echo.2014.01.001","article-title":"Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus","volume":"27","author":"Ernande","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.rceng.2019.10.012_bib0405","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/mrm.1910300207","article-title":"Improved myocardial tagging contrast","volume":"30","author":"Fischer","year":"1993","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0410","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.rceng.2019.10.012_bib0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/cvr\/cvs234","article-title":"Cardiotrophin-1 induces sarcoplasmic reticulum Ca(2+) leak and arrhythmogenesis in adult rat ventricular myocytes","volume":"96","author":"Ruiz-Hurtado","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0420","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1475-2840-12-150","article-title":"Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes","volume":"17","author":"Chen","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0425","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12020-009-9243-6","article-title":"Serum heart type fatty acid binding protein levels in metabolic syndrome","volume":"36","author":"Akbal","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/j.rceng.2019.10.012_bib0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037505","article-title":"Increased expression of fatty-acid and calcium metabolism genes in failing human heart","volume":"7","author":"Garc\u00eda-R\u00faa","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rceng.2019.10.012_bib0435","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7150\/ijms.14141","article-title":"Role of serum biomarkers in early detection of diabetic cardiomyopathy in the West Virginian Population","volume":"13","author":"Shaver","year":"2016","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.rceng.2019.10.012_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2007.07.057","article-title":"Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus","volume":"122","author":"Ihm","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0445","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.diabres.2010.01.004","article-title":"Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction","volume":"87","author":"Ban","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.rceng.2019.10.012_bib0450","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2014.08.018","article-title":"Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function?","volume":"114","author":"Gandhi","year":"2014","journal-title":"Am J Cardiol"},{"issue":"348 Pt","key":"10.1016\/j.rceng.2019.10.012_bib0455","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"15","author":"Owen","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.rceng.2019.10.012_bib0460","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1007\/s00125-013-2991-0","article-title":"Molecular mechanism of action of metformin: old or new insights?","volume":"56","author":"Rena","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.rceng.2019.10.012_bib0465","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.rceng.2019.10.012_bib0470","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cardfail.2009.10.022","article-title":"Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes","volume":"16","author":"Shah","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.rceng.2019.10.012_bib0475","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.rceng.2019.10.012_bib0480","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2006-1268","article-title":"Review: peroxisome proliferator-activated receptor gamma and adipose tissue \u2014 understanding obesity-related changes in regulation of lipid and glucose metabolism","volume":"92","author":"Sharma","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.rceng.2019.10.012_bib0485","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","article-title":"Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial","volume":"31","author":"Komajda","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2019.10.012_bib0490","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2337\/dc07-0717","article-title":"Pro. I. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2019.10.012_bib0495","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.rceng.2019.10.012_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2014.04.009","article-title":"Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection","volume":"3","author":"Ussher","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.rceng.2019.10.012_bib0505","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0510","first-page":"18","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0515","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0525","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.rceng.2019.10.012_bib0530","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/cvr\/cvy295","article-title":"Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies","volume":"115","author":"Chin","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.rceng.2019.10.012_bib0535","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.rceng.2019.10.012_bib0540","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0545","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.rceng.2019.10.012_bib0550","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0555","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2019.10.012_bib0560","doi-asserted-by":"crossref","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"issue":"November","key":"10.1016\/j.rceng.2019.10.012_bib0565","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2019.10.012_bib0570","first-page":"4","article-title":"A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study","volume":"11","author":"Jarnert","year":"2009","journal-title":"Eur Heart J"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S225488742030103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S225488742030103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:49:05Z","timestamp":1762418945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S225488742030103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S225488742030103X"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2019.10.012","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2019.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2019.10.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}